Samalizumab Explained

Samalizumab is a humanized monoclonal antibody designed for oncology indications.^[1] Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. ^[2]

Samalizumab was developed by Alexion Pharmaceuticals.

References

1. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab. American Medical Association.
2. Web site: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. .